Kiniksa (KNSA) CFO sale of 12,000 shares via 10b5-1 trading plan

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc reported that its Chief Financial Officer, Mark Ragosa, sold 12,000 Class A ordinary shares on January 8, 2026. The sale was coded as an open-market disposition and was carried out at a weighted average price of $41.89 per share, through multiple trades within a disclosed price range. The transaction was completed under a pre-arranged Rule 10b5-1 trading plan that the reporting person executed on August 14, 2025, indicating the sale followed a preset schedule rather than ad hoc market timing. Following this transaction, the CFO directly beneficially owns 19,086 Class A ordinary shares of the company.

Insider Trade Summary

Net Seller: 12,000 shares ($502,680)

Net Sell 1 txn

Insider Ragosa Mark

Role CHIEF FINANCIAL OFFICER

Sold 12,000 shs ($503K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Share	12,000	$41.89	$503K

Holdings After Transaction: Class A Ordinary Share — 19,086 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.44 and $42.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ragosa Mark

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INTERNATIONA

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	01/08/2026		S(1)		12,000	D	$41.89(2)	19,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.44 and $42.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

	/s/ Douglas Barry, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kiniksa (KNSA) disclose in this Form 4?

The company disclosed that its Chief Financial Officer, Mark Ragosa, sold 12,000 Class A ordinary shares of Kiniksa Pharmaceuticals International, plc.

On what date did the KNSA CFO sell shares and at what price?

The sale occurred on January 8, 2026, at a weighted average price of $41.89 per share, with individual trades executed between $41.44 and $42.24.

How many Kiniksa (KNSA) shares does the CFO hold after this transaction?

After the reported sale, the Chief Financial Officer beneficially owns 19,086 Class A ordinary shares directly.

Was the KNSA CFO share sale under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 plan executed by the reporting person on August 14, 2025.

What does the Form 4 say about the pricing of the KNSA share sale?

The sale was executed in multiple trades through a broker-dealer at prices between $41.44 and $42.24, with $41.89 reported as the weighted average sales price.

What is the reporting person’s role at Kiniksa Pharmaceuticals (KNSA)?

The reporting person, Mark Ragosa, is identified as an officer of Kiniksa Pharmaceuticals International, plc, serving as Chief Financial Officer.